RTW Investments LP Reduces Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

RTW Investments LP lowered its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 1.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,645,703 shares of the company’s stock after selling 30,000 shares during the period. Establishment Labs makes up approximately 1.7% of RTW Investments LP’s investment portfolio, making the stock its 24th biggest position. RTW Investments LP owned 0.09% of Establishment Labs worth $114,480,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ESTA. First Turn Management LLC purchased a new position in Establishment Labs in the second quarter worth about $16,812,000. Sofinnova Investments Inc. boosted its position in shares of Establishment Labs by 204.1% during the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company’s stock valued at $19,505,000 after buying an additional 288,082 shares during the period. Divisadero Street Capital Management LP purchased a new position in shares of Establishment Labs during the second quarter valued at approximately $5,829,000. Millennium Management LLC boosted its position in shares of Establishment Labs by 49.8% during the second quarter. Millennium Management LLC now owns 273,605 shares of the company’s stock valued at $12,433,000 after buying an additional 90,943 shares during the period. Finally, Rice Hall James & Associates LLC boosted its position in shares of Establishment Labs by 10.7% during the third quarter. Rice Hall James & Associates LLC now owns 793,300 shares of the company’s stock valued at $34,326,000 after buying an additional 76,959 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Citigroup boosted their target price on Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. Stephens restated an “overweight” rating and set a $68.00 target price on shares of Establishment Labs in a research report on Wednesday, August 7th. BTIG Research lifted their price target on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $60.60.

Establishment Labs Stock Performance

Establishment Labs stock opened at $44.17 on Thursday. The company has a 50 day moving average price of $43.49 and a 200-day moving average price of $44.55. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. Establishment Labs Holdings Inc. has a fifty-two week low of $22.05 and a fifty-two week high of $60.12. The company has a market capitalization of $1.24 billion, a PE ratio of -17.12 and a beta of 1.16.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.